Key Insights

Highlights

Success Rate

82% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

5.8%

4 terminated out of 69 trials

Success Rate

81.8%

-4.7% vs benchmark

Late-Stage Pipeline

7%

5 trials in Phase 3/4

Results Transparency

22%

4 of 18 completed with results

Key Signals

4 with results82% success

Data Visualizations

Phase Distribution

61Total
Not Applicable (5)
Early P 1 (1)
P 1 (17)
P 2 (33)
P 3 (5)

Trial Status

Unknown18
Completed18
Recruiting14
Not Yet Recruiting8
Terminated4
Active Not Recruiting4

Trial Success Rate

81.8%

Benchmark: 86.5%

Based on 18 completed trials

Clinical Trials (69)

Showing 20 of 20 trials
NCT07558083Phase 3RecruitingPrimary

FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients

NCT06589830Phase 2Recruiting

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

NCT04793958Phase 3Active Not RecruitingPrimary

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

NCT01822444CompletedPrimary

ANGIOPREDICT. ICORG 12-16, V3

NCT03699111CompletedPrimary

Identification of New Patient Stratification Tools in MSS RAS mt mCRC

NCT06369259Phase 2RecruitingPrimary

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

NCT06585488Phase 1Recruiting

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

NCT05194995Phase 1Active Not RecruitingPrimary

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

NCT07470658Enrolling By InvitationPrimary

Optimal Surveillance Strategy After Positive FIT and Negative Colonoscopy

NCT07321106Phase 1Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

NCT05424068Not ApplicableCompleted

Rehabilitation for People With Advanced Cancer

NCT07391618Phase 2RecruitingPrimary

Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU

NCT04744831Phase 2CompletedPrimary

Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

NCT07281157Phase 2RecruitingPrimary

Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer

NCT06824064Phase 2Recruiting

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

NCT07178613Phase 1Not Yet RecruitingPrimary

Assessment of the Dose Safety and Efficacy of Serine Combined With Fluorouracil Drugs

NCT06867822Phase 1RecruitingPrimary

Trial of ProAgio in Advanced/Metastatic Colorectal Cancer

NCT07106034Phase 2Not Yet RecruitingPrimary

Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial

NCT06199973Phase 3Active Not RecruitingPrimary

Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

NCT06885385Phase 2RecruitingPrimary

A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer

Scroll to load more

Research Network

Activity Timeline